Amarin (AMRN) Issued Patent 8,298,554 for Vascepa
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Up)Join SI Premium – FREE
Amarin Corporation plc (Nasdaq: AMRN) announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering the pharmaceutical composition of Amarin's VascepaTM (icosapent ethyl) capsules based on U.S. Patent Application Serial No. 12/769,885. On July 2, 2012, Amarin announced the issuance of a Notice of Allowance for claims under this application. The newly issued patent, U.S. Patent No. 8,298,554, is titled "Highly Stable EPA in a Capsule."
This issued patent has a term that expires no earlier than in 2030. Amarin plans to list this patent in the U.S. Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
"This patent issuance represents another step forward in Amarin's effort to protect the commercial potential of Vascepa," said Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer. "Amarin's goal is to protect the commercial potential of Vascepa to beyond 2030 through patent protection, regulatory exclusivity and trade secrets and by taking advantage of manufacturing barriers to entry."
This issued patent has a term that expires no earlier than in 2030. Amarin plans to list this patent in the U.S. Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
"This patent issuance represents another step forward in Amarin's effort to protect the commercial potential of Vascepa," said Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer. "Amarin's goal is to protect the commercial potential of Vascepa to beyond 2030 through patent protection, regulatory exclusivity and trade secrets and by taking advantage of manufacturing barriers to entry."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ocugen (OCGN) Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
- Ocular Therapeutix (OCUL) Reports Positive Topline Phase 1 Data for AXPAXLI
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
